163133-43-5

163133-43-5 structure

Name: Naproxcinod
Chemical Name: naproxcinod
CAS Number: 163133-43-5
Molecular Formula: C₁₈H₂₁NO₆
Molecular Weight: 347.36200
Catalog: Research Areas Inflammation/Immunology
Create Date: 2018-08-05 19:14:22
Modify Date: 2024-01-09 22:58:43
Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation[1][2][3].

Name	naproxcinod
Synonyms	Naproxcinod 2-(S)-(6-methoxy-2-naphthyl)-propanoic acid 4-nitroxybutyl ester HCT-3012 2-(S)-(6-methoxy-2-naphthyl)-propanoic acid nitrooxybutyl ester 4-nitrooxybutyl (2S)-2-(6-methoxynaphthalen-2-yl)propanoate Nitronaproxen 2-(S)-(6-methoxy-2-naphthyl)propanoic acid 4-(nitrooxy)butyl ester AZD-3582 (S)-2-(6-methoxy-2-naphthyl)propionic acid 4-nitrooxybutyl ester naproxen-n-butyl nitrate

Description	Naproxcinod (Nitronaproxen) is the first in class of cyclooxygenase (COX)-inhibiting nitric oxide donators (CINODs). Naproxcinod shows analgesic and anti-inflammatory effects, it can be used for the research of osteoarthritis and inflammation[1][2][3].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
In Vitro	Naproxcinod (1-30 μM; 15 min) concentration-dependently increases cGMP level up to 27-fold over basal level[1]. Naproxcinod (1-100 μM; 8 h) concentration-dependently increases HO-1 mRNA in endothelial cells[2]. Western Blot Analysis[2] Cell Line: Endothelial and gastric mucosal cell lines Concentration: 30-1000 μM Incubation Time: 8 and 24 hours Result: Increased HO-1 protein levels in endothelial and gastric mucosal cells and increased HO-1mRNA levels in endothelial cells.
In Vivo	Naproxcinod (0-41 mg/kg; p.o. once daily for 42 weeks) shows a significantly higher mean BW (7.3%) than vehicle group and improves skeletal and cardiac disease phenotype in the mouse model of DMD[3]. Animal Model: C57BL/10 mice with Duchenne muscular dystrophy (DMD)[3] Dosage: 0, 10, 21 and 41 mg/kg Administration: Oral gavage; 0-41 mg/kg once daily for 42 weeks Result: Significantly improved fraction shortening and ejection fraction, and reduced inflammation in vivo.
References	[1]. Berndt G, et al. A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. Eur J Pharm Sci. 2004 Feb;21(2-3):331-5. [2]. Berndt G, et al. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci. 2005 Jun;25(2-3):229-35. [3]. Uaesoontrachoon K, et al. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet. 2014 Jun 15;23(12):3239-49.

Density	1.213
Boiling Point	489.475ºC at 760 mmHg
Molecular Formula	C₁₈H₂₁NO₆
Molecular Weight	347.36200
Flash Point	193.208ºC
Exact Mass	347.13700
PSA	90.58000
LogP	4.00680

Precursor 9
1198786-35-4 1395256-92-4 22911-39-3 669692-75-5
22204-53-1 146563-40-8 51091-84-0 3457-91-8
26159-34-2
DownStream 0

1158522-08-7	940364-43-2
134104-43-1	131615-57-1
55686-82-3	6906-52-1
1039910-51-4	930439-75-1
1018584-77-4	1375289-11-4